Grifols

Grifols

Biotechnology
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

$3.6B

Market Cap • 9/10/2026

1987

(39 years)

Founded

2011

(15 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Spain

Spain

Country

Valuation

P/B

0,6

P/S

0,4

P/EBITDA

2,6

P/OCF

P/FCF

P/E

0,4

BVPS

13,5

EPS

1,1

Market Cap

Market Cap

3,6B

EV

16,2B

EV/Revenue

1,9

EV/EBITDA

11,6

EV/EBIT

11,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Dividend Yield 5Y

3,3%

Payout

0%

Retained Earnings

5,3B

Profitability

Gross Margin

68,9%

EBITDA Margin

16,2%

EBIT Margin

16,2%

Net Margin

7,8%

D&A/EBITDA

19,5%

R&D/Revenue

5,5%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

% PPE

20,2%

% Goodwill

35%

ROE

7,5%

ROIC

7%

Growth

CAGR Revenue 5Y

5,8%

CAGR Op. Income 5Y

1,7%

CAGR Net Income 5Y

-6,2%

CAGR EPS 5Y

50,4%

CAGR OCF 5Y

-100%

Leverage

N.D./EBITDA

7,1

Debt/Equity

0%

Current Ratio

2,4

Quick Ratio

0,7

Interest Coverage

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium